| 國立成功大學 |
2023 |
Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: a multicenter retrospective case–control study
|
Tsai, J.-H.;Li, C.-L.;Yeh, D.-C.;Hung, C.-S.;Hung, C.-C.;Lin, C.-Y.;Kuo, Y.-L. |
| 臺大學術典藏 |
2022-08-23T02:35:03Z |
Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders
|
Dai M.-S.; Liu L.-C.; Wang M.-Y.; Lo C.; Chang S.; Tan K.T.; Chen S.-J.; SUNG-HSIN KUO; Huang C.-S.; Yeh D.-C.; Tseng L.-M.; Lee Y.-H.; Chen S.-T.; Lin P.-H. |
| 臺大學術典藏 |
2022-08-12T06:27:35Z |
EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid
|
Yeh D.-C.; Chen D.-R.; Chao T.-Y.; Chen S.-C.; Wang H.-C.; Rau K.-M.; Feng Y.-H.; Chang Y.-C.; Lee K.-D.; Ou-Yang F.; Kuo W.-H.; KING-JEN CHANG; Lin Y.-C.; Tseng L.-M.; Hou M.-F. |
| 臺大學術典藏 |
2022-07-29T03:18:01Z |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
Lin P.-H.; Chen S.-C.; Tseng L.-M.; Chang K.-J.; Huang A.-C.; Cheng K.-C.; Yang K.; Wu H.-C.; Chao T.-Y.; Chang Y.-C.; Lin P.-C.; Kuo W.-H.; Kuo W.-L.; Lin C.-H.; Chen H.-M.; Yeh D.-C.; Liu L.-C.; Liu C.-Y.; MING-YANG WANG; Lo C.; Lu Y.-S.; Huang C.-S. |
| 臺大學術典藏 |
2022-07-29T03:18:01Z |
Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders
|
Lin P.-H.; Tseng L.-M.; Lee Y.-H.; Chen S.-T.; Yeh D.-C.; Dai M.-S.; Liu L.-C.; MING-YANG WANG; Lo C.; Chang S.; Tan K.T.; Chen S.-J.; Kuo S.-H.; Huang C.-S. |
| 臺大學術典藏 |
2022-05-11T08:25:41Z |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
Lin P.-H.; Chen S.-C.; Tseng L.-M.; Chang K.-J.; Huang A.-C.; Cheng K.-C.; Yang K.; Wu H.-C.; Chao T.-Y.; Chang Y.-C.; Lin P.-C.; Kuo W.-H.; Kuo W.-L.; CHING-HUNG LIN; Chen H.-M.; Yeh D.-C.; Liu L.-C.; Liu C.-Y.; Wang M.-Y.; Lo C.; Lu Y.-S.; Huang C.-S. |
| 臺大學術典藏 |
2022-03-15T05:39:30Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; WEI-WU CHEN; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2022-03-15T05:39:29Z |
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
|
Wu P.-F.; Lin C.-H.; Kuo C.-H.; WEI-WU CHEN; Yeh D.-C.; Liao H.-W.; Huang S.-M.; Cheng A.-L.; Lu Y.-S. |
| 臺大學術典藏 |
2022-03-15T05:39:25Z |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
|
WEI-WU CHEN; Yeh D.-C.; Chao T.-Y.; Lin C.-H.; Chow L.W.-C.; Chang D.-Y.; Hsieh Y.-Y.; Huang S.-M.; Cheng A.-L.; Lu Y.-S.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2022-03-10T02:31:33Z |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
PO-HAN LIN; Chen S.-C.; Tseng L.-M.; Chang K.-J.; Huang A.-C.; Cheng K.-C.; Yang K.; Wu H.-C.; Chao T.-Y.; Chang Y.-C.; Lin P.-C.; Kuo W.-H.; Kuo W.-L.; Lin C.-H.; Chen H.-M.; Yeh D.-C.; Liu L.-C.; Liu C.-Y.; Wang M.-Y.; Lo C.; Lu Y.-S.; Huang C.-S. |
| 國立成功大學 |
2022 |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
Lin, P.-H.;Chen, S.-C.;Tseng, L.-M.;Chang, K.-J.;Huang, A.-C.;Cheng, K.-C.;Yang, K.;Wu, H.-C.;Chao, T.-Y.;Chang, Y.-C.;Lin, P.-C.;Kuo, W.-H.;Kuo, W.-L.;Lin, C.-H.;Chen, H.-M.;Yeh, D.-C.;Liu, Liu L.-C.;Liu, C.-Y.;Wang, M.-Y.;Lo, C.;Lu, Y.-S.;Huang, C.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:51Z |
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
|
Wu P.-F.; Lin C.-H.; Kuo C.-H.; Chen W.-W.; Yeh D.-C.; Liao H.-W.; Huang S.-M.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:51Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; ANN-LII CHENG; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-08-31T06:29:30Z |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
|
Chen T.W.-W.; Yeh D.-C.; Chao T.-Y.; Lin C.-H.; Chow L.W.-C.; Chang D.-Y.; Hsieh Y.-Y.; Huang S.-M.; ANN-LII CHENG; Lu Y.-S.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-07-28T06:46:45Z |
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
|
Wu P.-F.; CHING-HUNG LIN; Kuo C.-H.; Chen W.-W.; Yeh D.-C.; Liao H.-W.; Huang S.-M.; Cheng A.-L.; Lu Y.-S. |
| 臺大學術典藏 |
2021-06-04T06:23:20Z |
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
|
Wu P.-F.; Lin C.-H.; CHING-HUA KUO; Chen W.-W.; Yeh D.-C.; Liao H.-W.; Huang S.-M.; Cheng A.-L.; Lu Y.-S. |
| 臺大學術典藏 |
2021-03-18T03:23:37Z |
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
|
Wu P.-F.; Lin C.-H.; Kuo C.-H.; WEI-WU CHEN; Yeh D.-C.; Liao H.-W.; Huang S.-M.; Cheng A.-L.; Lu Y.-S. |
| 臺大學術典藏 |
2021-03-18T03:23:37Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; WEI-WU CHEN; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-03-18T03:23:34Z |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
|
WEI-WU CHEN; Yeh D.-C.; Chao T.-Y.; Lin C.-H.; Chow L.W.-C.; Chang D.-Y.; Hsieh Y.-Y.; Huang S.-M.; Cheng A.-L.; Lu Y.-S.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-03-15T06:27:31Z |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
|
Chen T.W.-W.; Yeh D.-C.; Chao T.-Y.; Lin C.-H.; Chow L.W.-C.; DWANG-YING CHANG; Hsieh Y.-Y.; Huang S.-M.; Cheng A.-L.; Lu Y.-S.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-02-23T08:26:33Z |
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer
|
Lu Y.-S.; Chen D.-R.; Tseng L.-M.; Yeh D.-C.; Chen S.-T.; Hsieh C.-M.; Wang H.-C.; Yeh H.-T.; SUNG-HSIN KUO; Huang C.-S. |
| 臺大學術典藏 |
2020-08-06T07:51:48Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.;Chen T.W.-W.;Lin C.-H.;Yeh D.-C.;Tseng L.-M.;Wu P.-F.;Rau K.-M.;Chen B.-B.;Chao T.-C.;Huang S.-M.;Huang C.-S.;Tiffany Ting-Fang Shih;Cheng A.-L.;Taiwan Breast Cancer Consortium; Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; TIFFANY TING-FANG SHIH; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2020-05-25T06:52:00Z |
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer
|
Yen-Shen Lu;Chen D.-R;Tseng L.-M;Yeh D.-C;Chen S.-T;Hsieh C.-M;Wang H.-C;Yeh H.-T;Kuo S.-H;Huang C.-S.; YEN-SHEN LU; Chen D.-R; Tseng L.-M; Yeh D.-C; Chen S.-T; Hsieh C.-M; Wang H.-C; Yeh H.-T; Kuo S.-H; Huang C.-S. |
| 臺大學術典藏 |
2020-05-25T06:51:53Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Shih T.T.-F; Cheng A.-L; Taiwan Breast Cancer Consortium; Huang C.-S; Huang S.-M; Chao T.-C; Chen B.-B; Rau K.-M; Wu P.-F; Tseng L.-M; Yeh D.-C; Lin C.-H; Chen T.W.-W; YEN-SHEN LU; Taiwan Breast Cancer Consortium;Cheng A.-L;Shih T.T.-F;Huang C.-S;Huang S.-M;Chao T.-C;Chen B.-B;Rau K.-M;Wu P.-F;Tseng L.-M;Yeh D.-C;Lin C.-H;Chen T.W.-W;Yen-Shen Lu |
| 臺大學術典藏 |
2020-05-25T06:51:53Z |
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
|
Wu P.-F; Lin C.-H; Kuo C.-H; Chen W.-W; Yeh D.-C; Liao H.-W; Huang S.-M; Cheng A.-L; YEN-SHEN LU; Wu P.-F;Lin C.-H;Kuo C.-H;Chen W.-W;Yeh D.-C;Liao H.-W;Huang S.-M;Cheng A.-L;Yen-Shen Lu |
